1. Tran, E., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
2. Tran, E., et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 375, 2255-2262 (2016).
3. Stevanovic, S., et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356, 200-205 (2017).
4. Zacharakis, N., et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24, 724-730 (2018).
5. Parkhurst, M.R., et al. Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers. Cancer Discov 9, 1022-1035 (2019).
6. Robbins, P.F., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19, 747-752 (2013).
7. Cohen, C.J., et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125, 3981-3991 (2015).
8. Lane, D.P. Cancer. p53, guardian of the genome. Nature 358, 15-16 (1992).
9. Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 70, 7-30 (2020).
10. Malekzadeh, P., et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest 129, 1109-1114 (2019).
11. Deniger, D.C., et al. T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res 24, 5562-5573 (2018).
12. Lo, W., et al. Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. Cancer Immunol Res 7, 534-543 (2019).
13. Yossef, R., et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight 3(2018).
14. Hsiue, E.H., et al. Targeting a neoantigen derived from a common TP53 mutation. Science 371(2021).
15. Bouaoun, L., et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat 37, 865-876 (2016).
16. Bailey, M.H., et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173, 371-385 e318 (2018).
17. Rosenberg, S.A. & Restifo, N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62-68 (2015).
18. Krishna, S., et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328-1334 (2020).
19. Li, H., et al. Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell 176, 775-789 e718 (2019).
20. Oh, D.Y., et al. Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell 181, 1612-1625 e1613 (2020).
21. Miller, B.C., et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20, 326-336 (2019).
22. Wu, T.D., et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274-278 (2020).
23. Scott, A.C., et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270-274 (2019).
24. Sade-Feldman, M., et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell 175, 998-1013 e1020 (2018).
25. Tirosh, I., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196 (2016).
26. Duffy, M.J. & Crown, J. Drugging "undruggable" genes for cancer treatment: Are we making progress? Int J Cancer 148, 8-17 (2021).
27. Qasim, W., et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 9(2017).
28. Benjamin, R., et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885-1894 (2020).
29. Kreiter, S., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
30. Sahin, U., et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222-226 (2017).
31. Ott, P.A., et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217-221 (2017).
32. Sommermeyer, D., et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492-500 (2016).
33. McLane, L.M., Abdel-Hakeem, M.S. & Wherry, E.J. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol 37, 457-495 (2019).
34. Das, R.K., Vernau, L., Grupp, S.A. & Barrett, D.M. Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. Cancer Discov 9, 492-499 (2019).
35. Kochenderfer, J.N., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012).
36. Malekzadeh, P., et al. Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. Clin Cancer Res 26, 1267-1276 (2020).
37. Favero, F., et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol 26, 64-70 (2015).
38. Dilthey, A.T., et al. HLA*LA-HLA typing from linearly projected graph alignments. Bioinformatics 35, 4394-4396 (2019).
39. Bai, Y., Wang, D. & Fury, W. PHLAT: Inference of High-Resolution HLA Types from RNA and Whole Exome Sequencing. Methods Mol Biol 1802, 193-201 (2018).
40. McGranahan, N., et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell 171, 1259-1271 e1211 (2017).
41. Cohen, C.J., Zhao, Y., Zheng, Z., Rosenberg, S.A. & Morgan, R.A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 66, 8878-8886 (2006).
42. Morgan, R.A., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
43. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36, 411-420 (2018).
44. Stuart, T., et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888-1902 e1821 (2019).
45. Senbabaoglu, Y., et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol 17, 231 (2016).